ORPH.L Share News (ORPH)

ORPH.L Information

There is currently no data for ORPH

IN BRIEF: Open Orphan wins GBP5 million human challenge study pact

Fri, 25th Mar 2022 14:10

Open Orphan PLC - London-based pharmaceutical services firm - Says its subsidiary, hVIVO, wins contract with a European biotechnology company for a human challenge study. The GBP5 million contract with a European biotech seeks to test hVIVO's intravenous antiviral candidate. The study on the respiratory syncytial virus is expected to commence this year. Revenue from the deal will be recognised across 2022 and 2023.

Current stock price: 14.32 pence, up 6.1% on Friday

12-month change: down 50%

By Tom Budszus; tombudszus@alliancenews.com

More News

9 Jul 2021 11:42

Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug

9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

9 Jul 2021 10:20

Open Orphan subsidiary scores 'significant contract' with AIM ImmunoTech

(Sharecast News) - Clinical research organisation Open Orphan's hVIVO subsidiary has signed "a significant contract" to test AIM ImmunoTech's antiviral candidate, Ampligen.

17 Jun 2021 14:34

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

17 Jun 2021 14:05

Open Orphan reports widened 2020 loss; Poolbeg mulls London float

17 Jun 2021 11:43

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

16 Jun 2021 16:00

UK earnings, trading statements calendar - next 7 days

19 May 2021 19:33

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

10 May 2021 13:37

TRADING UPDATES: Begbies buys finance broker; Amino Tech makes US bid

10 May 2021 09:30

Open Orphan subsidiary signs contract to make Covid-19 challenge virus

(Sharecast News) - Specialist pharmaceutical services contract research organisation Open Orphan announced on Monday that its subsidiary hVIVO has signed a contract with Imperial College London, as part of a Wellcome Trust-funded initiative to manufacture a SARS-CoV-2 challenge virus.

6 May 2021 15:33

EXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO

9 Apr 2021 10:33

Open Orphan launches new data platform to combat infectious diseases

26 Mar 2021 14:36

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

25 Mar 2021 17:14

TRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus

25 Mar 2021 15:34

Open Orphan makes progress with Covid-19 characterisation study

(Sharecast News) - Specialist pharmaceutical services clinical research company Open Orphan updated the market on its world-first Covid-19 characterisation study on Thursday, reporting that the first three volunteers had now completed the quarantine phase.

Latest Share Chat

ORPH.L Share News (ORPH)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Open Orphan wins GBP5 million human challenge study pact

Login to your account

Quickpicks are a member only feature

Login to your account